The discovery of MPN driver mutations, particularly Janus Kinase 2 (JAK2), in GPI-deficient cells has sparked the hypothesis that these mutations could provide PNH cells with a natural growth advantage [61]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.